UBS Raises Scotts Miracle-Gro Price Target to $77, Keeps Buy Rating
UBS increased its price target from $70 to $77 and maintained its Buy rating, following the company’s fiscal fourth-quarter results and fiscal 2027 guidance.
UBS increased its price target from $70 to $77 and maintained its Buy rating, following the company’s fiscal fourth-quarter results and fiscal 2027 guidance.